The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment
Open Access
- 9 April 2022
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 11 (4) , 500
Abstract
Bacterial vaginosis (BV), the most common cause of vaginal discharge, is characterized by a shift in the vaginal microbiota from Lactobacillus species dominance to a diverse array of facultative and strict anaerobic bacteria which form a multi-species biofilm on vaginal epithelial cells. The rate of BV recurrence after therapy is high, often >60%. The BV biofilm itself likely contributes to recurrent and refractory disease after treatment by reducing antimicrobial penetration. However, antimicrobial resistance in BV-associated bacteria, including those both within the biofilm and the vaginal canal, may be the result of independent, unrelated bacterial properties. In the absence of new, more potent antimicrobial agents to eradicate drug-resistant pathogenic vaginal microbiota, treatment advances in refractory and recurrent BV have employed new strategies incorporating combination therapy. Such strategies include the use of combination antimicrobial regimens as well as alternative approaches such as probiotics and vaginal fluid transfer. Our current recommendations for the treatment of refractory and recurrent BV are provided.Keywords
All Related Versions
Funding Information
- National Institute of Health (R01AI146065-01A1, R21AI167754-01)
This publication has 46 references indexed in Scilit:
- Analysis of adherence, biofilm formation and cytotoxicity suggests a greater virulence potential of Gardnerella vaginalis relative to other bacterial-vaginosis-associated anaerobesMicrobiology, 2010
- Probiotics for the treatment of bacterial vaginosisCochrane Database of Systematic Reviews, 2009
- Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosisIndian Journal of Medical Microbiology, 2008
- An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazoleAmerican Journal of Obstetrics and Gynecology, 2008
- A Randomized Trial of the Duration of Therapy with Metronidazole plus or minus Azithromycin for Treatment of Symptomatic Bacterial VaginosisClinical Infectious Diseases, 2007
- Adherent Biofilms in Bacterial VaginosisObstetrics & Gynecology, 2005
- Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: A randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2004
- Antimicrobial resistance associated with the treatment of bacterial vaginosisAmerican Journal of Obstetrics and Gynecology, 2004
- Gardnerella vaginalisIsolated from Patients with Bacterial Vaginosis and from Patients with Healthy Vaginal EcosystemsClinical Infectious Diseases, 2001
- Prevalence and Characteristics of nim Genes Encoding 5-Nitroimidazole Resistance among Bacteroides Strains Isolated in MoroccoMicrobial Drug Resistance, 2001